Bioactive properties and clinical safety of a novel milk protein peptide

Nutrition Journal

Men-Hwei Tsai⁵  Olof Mollstedt⁵  Helen Chen⁵  Chris Rasmussen²  Geoffrey Hudson¹  Matt Cooke⁴  Mike Iosia³  Richard B Kreider² 

[1] School of Human Performance and Recreation, University of Southern Mississippi, Hattiesburg, MS 39406, USA;Exercise and Sport Nutrition Laboratory, Department of Health & Kinesiology, Texas A&M University College Station, TX 77843-4243, USA;Department of Health, Exercise Science, and Secondary Education, Lee University, Cleveland, TN 37320, USA;Schools of Biomedical & Health Sciences, Victoria University, Melbourne Victoria 8001, Australia;Ambryx Biotechnology, Inc., Riverside, CA, 92507-2155, USA

关键词: Quality of Life;    Insulin Sensitivity;    Neutrophil Lymphocyte Ratio;    Cancer;    Health;   

Others  :  828725
DOI  :  10.1186/1475-2891-10-99

 received in 2011-08-11, accepted in 2011-09-26,  发布年份 2011

【 摘 要 】

Background

Milk protein fractions and peptides have been shown to have bioactive properties. This preliminary study examined the potential mechanisms of action and clinical safety of novel milk protein peptide (MP).

Findings

A novel MP mixture inhibits the tyrosine kinase activity of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2), and insulin receptor (IR) with IC₅₀ of 9.85 μM, 7.7 μM, and 6.18 μM respectively. In vitro, this multi-kinase inhibitor causes apoptosis in HT-29 colon cancer cells, and in a C. elegans worm study, showed a weak but significant increase in lifespan. A six week double-blind, placebo-controlled study involving 73 healthy volunteers demonstrated that the MP mixture is safe to consume orally. All clinical blood markers remained within normal levels and no clinically significant side effects were reported. There was some evidence of improved insulin sensitivity, neutrophil-to-lymphocyte ratio (NLR), and quality of life assessment of role of physical function.

Conclusions

These data in combination with the observed in vitro anti-cancer properties warrant further clinical studies to investigate this MP mixture as a potential clinical nutrition intervention for improving the quality of life and clinical outcomes in cancer patients.

Trial Registration

NCT01412658

【 授权许可】

   
2011 Kreider et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Nagpal R, Behare P, Rana R, Kumar A, Kumar M, Arora S, Morotta F, Jain S, Yadav H: Bioactive peptides derived from milk proteins and their health beneficial potentials: an update. Food Funct 2011, 2:18-27.
• [2]Lien E, Jackson J, Kuhlman C, Pramuk K, Lonnerdal B, Janszen D: Variations in concentrations of lactoferrin in human milk: a nine country survey. Adv Exp Med Biol 2004, 554:423-426.
• [3]Domellof M, Hemell O, Dewey KG, Cohen RJ, Lonnerdal B: Factors influencing concentrations of iron, zinc, and copper in human milk. Adv Exp Med Biol 2004, 554:355-358.
• [4]Kaminsky LA, Bryant CX, Mahler DA, Durstine JL, Humphrey RH: ACSM's Guidelines for Exercise Testing and Prescription. 8th edition. Baltimore, MD: Lippincott, Williams & Wilkins; 2009.
• [5]Cuka S, Dvornik S, Drazenovic K, Mihic J: Evaluation of the Dade Behring Dimension RxL clinical chemistry analyzer. Clin Lab 2001, 47:35-40.
• [6]McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW: Diagnosing insulin resistance in the general population. Diabetes Care 2001, 24:460-464.
• [7]Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A: Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995, 33:AS264-279.
• [8]Lonnerdal B: Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr 2003, 77:1537S-1543S.
• [9]Lonnerdal B: Human milk proteins: key components for the biological activity of human milk. Adv Exp Med Biol 2004, 554:11-25.
• [10]Jain A, Lense S, Linehan JC, Raugei S, Cho H, DuBois DL, Shaw WJ: Incorporating peptides in the outer-coordination sphere of bioinspired electrocatalysts for hydrogen production. Inorg Chem 2011, 50:4073-4085.
• [11]Korhonen H, Pihlanto A: Food-derived bioactive peptides--opportunities for designing future foods. Curr Pharm Des 2003, 9:1297-1308.
• [12]Vermeirssen V, Van Camp J, Verstraete W: Bioavailability of angiotensin I converting enzyme inhibitory peptides. Br J Nutr 2004, 92:357-366.
• [13]Phelan M, Kerins D: The potential role of milk-derived peptides in cardiovascular disease. Food Funct 2011, 2:153-167.
• [14]Drouet L, Bal Dit Sollier C, Mazoyer E, Levy-Toledano S, Jolles P, Fiat A: Use of k- caseinoglycopeptide for preparation of composition, especially a drug, for prevention and treatment of thrombosis. 1990. EP0397571
• [15]Drouet L, Bal Dit Sollier C, Mazoyer E, Levy-Toledano S, Jolles P, Fiat A: Method of preventing or treating thrombosis using kappa-caseinoglycopeptide as active ingredient. 1990. US5063203
• [16]Khazaie K, Schirrmacher V, Lichtner RB: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993, 12:255-274.
• [17]Lurje G, Lenz HJ: EGFR signaling and drug discovery. Oncology 2009, 77:400-410.
• [18]Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K: Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res 2010, 70:10402-10410.
• [19]Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R: A C. elegans mutant that lives twice as long as wild type. Nature 1993, 366:461-464.
• [20]Baumeister R, Schaffitzel E, Hertweck M: Endocrine signaling in Caenorhabditis elegans controls stress response and longevity. J Endocrinol 2006, 190:191-202.
• [21]Chua W, Charles KA, Baracos VE, Clarke SJ: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011, 104:1288-1295.
• [22]Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, et al.: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010, 25:1427-1433.
• [23]Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005, 91:181-184.
• [24]Brekken RA, Thorpe PE: Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 2001, 21:4221-4229.
• [25]Shibuya M: Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006, 13:63-69.